1  and fluconazole tablets in the treatment of esophageal candidiasis.

2 s against Pneumocystis carinii pneumonia and esophageal candidiasis.

3 reased relative rate of 0.61 (P = 0.005) for esophageal candidiasis.

4 vasive fungal infection and the treatment of esophageal candidiasis.

5                         Five patients showed esophageal candidiasis, and 2 had eosinophilic esophagit

6 Is included Pneumocystis jiroveci pneumonia, esophageal candidiasis, and disseminated Mycobacterium a

7 sease, PCP, CMV retinitis, Kaposi's sarcoma, esophageal candidiasis, CMV disease, extrapulmonary cryp

8 most frequent OIs were PCP, MAC disease, and esophageal candidiasis; decreasing trends occurred for 5

9 ns with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug wa

10 e and is an alternative for the treatment of esophageal candidiasis in immunocompromised patients.

11                                              Esophageal candidiasis (n = 7) was associated with prove

12                            Oropharyngeal and esophageal candidiasis (OPEC) is a frequent opportunisti

13 2), cryptococcal infection (P=0.01), oral or esophageal candidiasis (P=0.02), death of unknown cause

14                                              Esophageal candidiasis responds to escalating doses of m

15 black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased r

16 ; decreasing trends occurred for 5 OIs (PCP, esophageal candidiasis, tuberculosis, chronic herpes sim

17 th potent anti-Candida activity, in treating esophageal candidiasis was tested in a double-blind stud

18 d twenty-six immunocompromised patients with esophageal candidiasis were treated with itraconazole or